The Benefits of PET Imaging

The Benefits of PET Imaging

PET Imaging in Alzheimer’s Disease Research

Positron emission tomography (PET) imaging is a powerful tool used to study brain changes associated with Alzheimer’s disease (AD). PET scans allow researchers to visualize specific proteins in the living brain, making it possible to detect disease-related changes years before symptoms appear.

Two key PET imaging approaches are used in Alzheimer’s research: amyloid PET imaging and tau PET imaging. Each provides distinct and complementary information about the biological processes underlying the disease.

One of the hallmark features of Alzheimer’s disease is the buildup of amyloid beta plaques in the brain. Amyloid beta is a protein that normally occurs in the body but can misfold and accumulate in the brain over time.

Historically, Alzheimer’s disease could only be definitively diagnosed after death by identifying amyloid plaques in brain tissue. Today, amyloid PET imaging makes it possible to detect elevated levels of amyloid plaque in the brain years before cognitive symptoms develop.

The presence of amyloid plaque does not guarantee that a person will develop Alzheimer’s disease, but it does increase risk. Identifying amyloid early is important for both research and clinical care.

Recently approved medications that reduce brain amyloid plaque can slow the progression of cognitive symptoms in some individuals with Alzheimer’s disease. Before these treatments can be used, confirmation of elevated brain amyloid is required.

This confirmation can be obtained through:

  • Amyloid PET imaging, or
  • Cerebrospinal fluid (CSF) biomarkers collected via spinal tap

Amyloid PET imaging provides a non-invasive way to determine whether amyloid plaque is present and at what level.

In a research setting, the Cleveland Alzheimer’s Disease Research Center (CADRC) uses amyloid PET imaging to identify and quantify amyloid plaque burden in study participants, helping researchers understand early disease markers and track changes over time.

PET Imaging in Alzheimer’s Disease Research

Positron emission tomography (PET) imaging is a powerful tool used to study brain changes associated with Alzheimer’s disease (AD). PET scans allow researchers to visualize specific proteins in the living brain, making it possible to detect disease-related changes years before symptoms appear.

Two key PET imaging approaches are used in Alzheimer’s research: amyloid PET imaging and tau PET imaging. Each provides distinct and complementary information about the biological processes underlying the disease.

One of the hallmark features of Alzheimer’s disease is the buildup of amyloid beta plaques in the brain. Amyloid beta is a protein that normally occurs in the body but can misfold and accumulate in the brain over time.

Historically, Alzheimer’s disease could only be definitively diagnosed after death by identifying amyloid plaques in brain tissue. Today, amyloid PET imaging makes it possible to detect elevated levels of amyloid plaque in the brain years before cognitive symptoms develop.

The presence of amyloid plaque does not guarantee that a person will develop Alzheimer’s disease, but it does increase risk. Identifying amyloid early is important for both research and clinical care.

Recently approved medications that reduce brain amyloid plaque can slow the progression of cognitive symptoms in some individuals with Alzheimer’s disease. Before these treatments can be used, confirmation of elevated brain amyloid is required.

This confirmation can be obtained through:

  • Amyloid PET imaging, or
  • Cerebrospinal fluid (CSF) biomarkers collected via spinal tap

Amyloid PET imaging provides a non-invasive way to determine whether amyloid plaque is present and at what level.

In a research setting, the Cleveland Alzheimer’s Disease Research Center (CADRC) uses amyloid PET imaging to identify and quantify amyloid plaque burden in study participants, helping researchers understand early disease markers and track changes over time.

Interpreting Amyloid PET Images

Amyloid PET images show how much tracer binds to amyloid plaque in different areas of the brain. Darker areas indicate higher tracer uptake.

Some tracer uptake is normal in deeper brain structures and the scalp. In Alzheimer’s disease, amyloid plaques accumulate primarily in the cortical (outer) regions of the brain.

Amyloid burden is often summarized using a standardized value called the Centiloid score:

  • A score near 0 is typical of individuals without elevated brain amyloid
  • A score near 100 is typical of individuals with Alzheimer’s disease
  • Scores can fall below 0 or above 100, depending on tracer uptake

Interpreting Amyloid PET Images

Amyloid PET images show how much tracer binds to amyloid plaque in different areas of the brain. Darker areas indicate higher tracer uptake.

Some tracer uptake is normal in deeper brain structures and the scalp. In Alzheimer’s disease, amyloid plaques accumulate primarily in the cortical (outer) regions of the brain.

Amyloid burden is often summarized using a standardized value called the Centiloid score:

  • A score near 0 is typical of individuals without elevated brain amyloid
  • A score near 100 is typical of individuals with Alzheimer’s disease
  • Scores can fall below 0 or above 100, depending on tracer uptake

Tau PET Imaging

In addition to amyloid plaques, abnormal tau protein deposits play a critical role in Alzheimer’s disease. Unlike amyloid plaques, which form between brain cells, tau deposits — known as neurofibrillary tangles — form inside brain cells and directly damage them.

Importantly, the appearance and spread of tau deposits are closely linked to the onset and severity of cognitive symptoms in Alzheimer’s disease.

While amyloid can accumulate years before symptoms appear, tau pathology tends to emerge around the time cognitive changes begin.

Detecting Tau in the Brain

Tau deposits can be detected using:

  • Cerebrospinal fluid or blood biomarkers, or
  • Tau PET imaging

To a research participant, a tau PET scan feels nearly identical to an amyloid PET scan. The key difference lies in the tracer that is injected.

In tau PET imaging, the tracer is designed to bind specifically to tau protein rather than amyloid plaque. The resulting images show the distribution and extent of tau pathology in the brain.

Because PET scanners cannot distinguish between different tracers, amyloid PET and tau PET scans must be performed on separate days, allowing time for one tracer to clear from the body before the other is administered.

Tau PET Imaging

In addition to amyloid plaques, abnormal tau protein deposits play a critical role in Alzheimer’s disease. Unlike amyloid plaques, which form between brain cells, tau deposits — known as neurofibrillary tangles — form inside brain cells and directly damage them.

Importantly, the appearance and spread of tau deposits are closely linked to the onset and severity of cognitive symptoms in Alzheimer’s disease.

While amyloid can accumulate years before symptoms appear, tau pathology tends to emerge around the time cognitive changes begin.

Detecting Tau in the Brain

Tau deposits can be detected using:

  • Cerebrospinal fluid or blood biomarkers, or
  • Tau PET imaging

To a research participant, a tau PET scan feels nearly identical to an amyloid PET scan. The key difference lies in the tracer that is injected.

In tau PET imaging, the tracer is designed to bind specifically to tau protein rather than amyloid plaque. The resulting images show the distribution and extent of tau pathology in the brain.

Because PET scanners cannot distinguish between different tracers, amyloid PET and tau PET scans must be performed on separate days, allowing time for one tracer to clear from the body before the other is administered.

Why PET Imaging Matters

Together, amyloid and tau PET imaging provide complementary insights into Alzheimer’s disease:

  • Amyloid PET identifies early disease-related changes and treatment eligibility
  • Tau PET reflects neuronal injury and cognitive decline

By combining these tools, researchers at CADRC can better understand disease progression, improve diagnosis, and advance the development of new therapies.

Why PET Imaging Matters

Together, amyloid and tau PET imaging provide complementary insights into Alzheimer’s disease:

  • Amyloid PET identifies early disease-related changes and treatment eligibility
  • Tau PET reflects neuronal injury and cognitive decline

By combining these tools, researchers at CADRC can better understand disease progression, improve diagnosis, and advance the development of new therapies.

Looking for More Info on Dementia and Alzheimer’s Disease?

contact@clevelandadrc.org

Looking for More Info on Dementia and Alzheimer’s Disease?

contact@clevelandadrc.org

Get the Latest News & Research Updates with the Mind Matters Newsletter

Get the latest news, research updates, and community events from the Cleveland Alzheimer’s Disease Research Center. Our quarterly newsletter Mind Matters shares stories of progress, education, and hope – keeping you informed and involved in the fight against Alzheimer’s disease and related dementias.